People · Operator
Named in public records as an officer, director or promoter · active 2016–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Progenity, Inc. | — | Biotechnology | Series C | $141.6M | $409.6M | 2016 |
| Secura Bio Holdings, Inc. | — | Pharmaceuticals | Series D+ | $105.0M | $3.7B | 2019 |
Jeffrey Ferrell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Ferrell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Harry Stylli | 1 | 3 |
| Brett Lund | 1 | 3 |
| Juan Estruch | 1 | 3 |
| Jeffrey Alter | 1 | 3 |
| Mark Spring | 1 | 2 |
| Howard Slutsky | 1 | 2 |
| Sumit Aggarwal | 1 | 2 |
| Samuel Nussbaum | 1 | 2 |
| Brian Kotzin | 1 | 2 |
| Joseph Limber | 1 | 2 |
| Paul Hawran | 1 | 1 |
| John Bigalke | 1 | 1 |
| Lynne Powell | 1 | 1 |
| Clarke Neumann | 1 | 1 |
| Eric d'Esparbes | 1 | 1 |
| Eric Fox | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.